Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
ANRO Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ANRO Stock 12 Month Forecast
Average Price Target
$30.71
▲(80.33% Upside)
| Highest Price Target$50.00 | Average Price Target$30.71 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$27
Buy
58.54%
Upside
Reiterated
12/02/25
Jefferies
$25
Buy
46.80%
Upside
Reiterated
11/18/25
H.C. Wainwright
$50
Buy
193.60%
Upside
Reiterated
11/17/25
Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial PositionWe value Alto Neuroscience using a sum-of-the-parts (SOTP) and risk-adjusted discounted cash flow (DCF) methodology. We assign probabilities of success of 30% to BPD, reflecting varying levels of clinical maturity and risk. We model annual equity raises of $100M-$200M from 2026E to 2029E, to fund clinical development and potential commercial launch expenses, which could dilute existing shareholders.
Stifel Nicolaus
$33
Buy
93.78%
Upside
Reiterated
11/14/25
TD Cowen
―
Buy
―
Reiterated
11/13/25
William Blair
―
Buy
―
Reiterated
11/12/25
JonesTrading
$13→$49
Buy
187.73%
Upside
Reiterated
11/12/25
Alto Neuroscience's ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial ProjectionsWe now include risk-adjusted revenues (25% probability of success) for ALTO-207 in TRD in our model (Exhibit 1: Market Model ). This includes peak risk-adjusted net U.S. sales of $1.95B in 2033. ALTO-207 now represents a core value driver in our model, accounting for 54% of total FY36 revenue (the terminal year in our model).
Chardan Capital
$15
Buy
-11.92%
Downside
Reiterated
10/20/25
Robert W. Baird
$10→$16
Buy
-6.05%
Downside
Reiterated
10/20/25
Wedbush
$4
Hold
-76.51%
Downside
Reiterated
06/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$27
Buy
58.54%
Upside
Reiterated
12/02/25
Jefferies
$25
Buy
46.80%
Upside
Reiterated
11/18/25
H.C. Wainwright
$50
Buy
193.60%
Upside
Reiterated
11/17/25
Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial PositionWe value Alto Neuroscience using a sum-of-the-parts (SOTP) and risk-adjusted discounted cash flow (DCF) methodology. We assign probabilities of success of 30% to BPD, reflecting varying levels of clinical maturity and risk. We model annual equity raises of $100M-$200M from 2026E to 2029E, to fund clinical development and potential commercial launch expenses, which could dilute existing shareholders.
Stifel Nicolaus
$33
Buy
93.78%
Upside
Reiterated
11/14/25
TD Cowen
―
Buy
―
Reiterated
11/13/25
William Blair
―
Buy
―
Reiterated
11/12/25
JonesTrading
$13→$49
Buy
187.73%
Upside
Reiterated
11/12/25
Alto Neuroscience's ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial ProjectionsWe now include risk-adjusted revenues (25% probability of success) for ALTO-207 in TRD in our model (Exhibit 1: Market Model ). This includes peak risk-adjusted net U.S. sales of $1.95B in 2033. ALTO-207 now represents a core value driver in our model, accounting for 54% of total FY36 revenue (the terminal year in our model).
Chardan Capital
$15
Buy
-11.92%
Downside
Reiterated
10/20/25
Robert W. Baird
$10→$16
Buy
-6.05%
Downside
Reiterated
10/20/25
Wedbush
$4
Hold
-76.51%
Downside
Reiterated
06/27/25
Best Analysts Covering Alto Neuroscience, Inc.
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+13.94%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +13.94% per trade.
3 Months
xxx
Success Rate
7/7 ratings generated profit
Average Return
+100.97%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +100.97% per trade.
1 Year
Success Rate
10/10 ratings generated profit
Average Return
+326.64%
reiterated a buy rating last month
Copying Justin Walsh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +326.64% per trade.
2 Years
xxx
Success Rate
10/10 ratings generated profit
Average Return
+326.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +326.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ANRO Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
14
13
9
12
10
Buy
6
5
6
6
6
Hold
2
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
19
15
18
16
Each month's total comprises the sum of three months' worth of ratings.
ANRO Financial Forecast
ANRO Stock Forecast FAQ
What is ANRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Alto Neuroscience, Inc.’s 12-month average price target is 30.71.
What is ANRO’s upside potential, based on the analysts’ average price target?
Alto Neuroscience, Inc. has 80.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ANRO a Buy, Sell or Hold?
Alto Neuroscience, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Alto Neuroscience, Inc.’s price target?
The average price target for Alto Neuroscience, Inc. is 30.71. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $15.00. The average price target represents 80.33% Increase from the current price of $17.03.
The highest analyst price target is $50.00 ,the lowest forecast is $15.00. The average price target represents 80.33% Increase from the current price of $17.03.
What do analysts say about Alto Neuroscience, Inc.?
Alto Neuroscience, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of ANRO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.